Wladimir Bocca Vieira de Rezende Pinto

Dr. Wladimir Bocca Vieira de Rezende Pinto

Universidade Federal de São Paulo, São Paulo, Brazil
orcid
Assistant Neurologist; Division of Neuromuscular Disorders, ...

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in The Lancet Neurology
Verified
Journal Article
Closed access
JHJames F Howard
James F Howard
KUKimiaki Utsugisawa
Kimiaki Utsugisawa
MBMichael Benatar
Michael Benatar
HMHiroyuki Murai
Hiroyuki Murai
RBRichard J Barohn
Richard J Barohn
HVHong Vu
Hong Vu

7 June 2016 in The Cerebellum
Verified
Journal Article
Closed access
PDF file
PSPaulo Victor Sgobbi de Souza
Paulo Victor Sgobbi de Souza
Wladimir Bocca Vieira de Rezende PintoWladimir Bocca Vieira de Rezende Pinto
Wladimir Bocca Vieira de Rezende Pinto
GBGabriel Novaes de Rezende Batistella
Gabriel Novaes de Rezende Batistella
TBThiago Bortholin
Thiago Bortholin
AOAcary Souza Bulle Oliveira
Acary Souza Bulle Oliveira

11 September 2020 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
ACAntonio E. Camelo-Filho
Antonio E. Camelo-Filho
ASAndré M. S. Silva
André M. S. Silva
EEEduardo P. Estephan
Eduardo P. Estephan
AZAntônio A. Zambon
Antônio A. Zambon
RMRodrigo H. Mendonça
Rodrigo H. Mendonça
EZEdmar Zanoteli
Edmar Zanoteli
Myasthenia gravis (MG), an autoimmune neuromuscular disorder, may be a risk factor for severe COVID-19. We conducted an observational retrospective study with 15 consecutive adult MG patients admitted with COVID-19 at four hospitals in São Paulo, Brazil. Most patients with MG hospitalized for COVID-19 had severe courses of the disease: 87% were admitted in the intensive care unit, 73% needed mechanical ventilation, and 30% died. Immunoglobulin use and the plasma exchange procedure were safe. Immunosuppressive therapy seems to be associated with better outcomes, as it might play a protective role.

23 December 2022 in Frontiers in Neurology
Verified
Journal Article
Open access
PNPaulo Ribeiro Nóbrega
Paulo Ribeiro Nóbrega
ABAnderson Moura Bernardes
Anderson Moura Bernardes
RRRodrigo Mariano Ribeiro
Rodrigo Mariano Ribeiro
SVSophia Costa Vasconcelos
Sophia Costa Vasconcelos
DADavid Augusto Batista Sá Araújo
David Augusto Batista Sá Araújo
PBPedro Braga-Neto
Pedro Braga-Neto
Cerebrotendinous Xanthomatosis represents a rare and underdiagnosed inherited neurometabolic disorder due to homozygous or compound heterozygous variants involving the CYP27A1 gene. This bile acid metabolism disorder represents a key potentially treatable neurogenetic condition due to the wide spectrum of neurological presentations in which it most commonly occurs. Cerebellar ataxia, peripheral neuropathy, spastic paraparesis, epilepsy, parkinsonism, cognitive decline, intellectual disability, and neuropsychiatric disturbances represent some of the most common neurological signs observed in this condition. Despite representing key features to increase diagnostic index suspicion, multisystemic involvement does not represent an obligatory feature and can also be under evaluated during diagnostic work-up. Chenodeoxycholic acid represents a well-known successful therapy for this inherited metabolic disease, however its unavailability in several contexts, high costs and common use in patients at late stages of disease course limit more favorable neurological outcomes for most individuals. This review article aims to discuss and highlight the most recent and updated knowledge regarding clinical, pathophysiological, neuroimaging, genetic and therapeutic aspects related to Cerebrotendinous Xanthomatosis.

14 October 2020 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
Wladimir Bocca Vieira de Rezende PintoWladimir Bocca Vieira de Rezende Pinto
Wladimir Bocca Vieira de Rezende Pinto
ARAuro Ricarte
Auro Ricarte
BBBruno de Mattos Lombardi Badia
Bruno de Mattos Lombardi Badia
DSDaniel Delgado Seneor
Daniel Delgado Seneor
AOAcary Souza Bulle Oliveira
Acary Souza Bulle Oliveira

5 October 2020 in Neurology Genetics
Verified
Journal Article
Open access
PDF file
RMRodrigo de Holanda Mendonça
Rodrigo de Holanda Mendonça
CMCiro Matsui
Ciro Matsui
GPGraziela Jorge Polido
Graziela Jorge Polido
ASAndré Macedo Serafim Silva
André Macedo Serafim Silva
LKLeslie Kulikowski
Leslie Kulikowski
EZEdmar Zanoteli
Edmar Zanoteli
Objective The aim of the study was to report the proportion of homozygous and compound heterozygous variants in the survival motor neuron 1 (SMN1) gene in a large population of patients with spinal muscular atrophy (SMA) and to correlate the severity of the disease with the presence of specific intragenic variants in SMN1 and with the SMN2 copy number. Methods Four hundred fifty Brazilian patients with SMA were included in a retrospective study, and clinical data were analyzed compared with genetic data; the SMN2 copy number was obtained by multiplex ligation-dependent probe amplification and pathogenic variants in SMN1 by next-generation sequencing. Results Four hundred two patients (89.3%) presented homozygous exon 7-SMN1 deletion, and 48 (10.7%) were compound heterozygous for the common deletion in one allele and a point mutation in the other allele. Recurrent variants in exons 3 and 6 (c.460C>T, c.770_780dup and c.734_735insC) accounted for almost 80% of compound heterozygous patients. Another recurrent pathogenic variant was c.5C>G at exon 1. Patients with c.770_780dup and c.734_735insC had a clinical phenotype correlated with SMN2 copy number, whereas the variants c.460C>T and c.5C>G determined a milder phenotype independently of the SMN2 copies. Conclusions Patients with specific pathogenic variants (c.460C>T and c.5C>G) presented a milder phenotype, and the SMN2 copy number did not correlate with disease severity in this group.